Bio Products Opportunity

UBS Investment Research analyst Maged Shenouda initiated coverage of biotechnology company Genentech Inc. with a “Buy” rating and $101 price target Friday, citing its solid line of cancer treatments.

Original post by Lyle

This entry was posted on Friday, September 21st, 2007 at 11:42 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.